FDA Says All Options on the Table at LDT Meeting

"LDTs have become a lot more like IVDs," said an FDA official. "So the logical basis for a bifurcated regulatory pathway has also faded."

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.

Related Stories